Hemolysis

Chronic and excessive hemolysis (the destruction of red blood cells) is the main cause of serious health problems in people with PNH.9 Hemolysis can be measured by LDH (lactate dehydrogenase), an enzyme that is found in many organs and tissues of the body, but is especially abundant in red blood cells. Elevated levels of LDH are an indicator of excessive hemolysis.8

Destruction of Red Blood Cells

In healthy individuals, red blood cells are equipped with a surface protein, known as a complement inhibitor, which protects them from naturally occurring levels of complement and prevents cell destruction. Patients with PNH lack the protective complement inhibitor protein, thus allowing red blood cells to be susceptible to low levels of complement activity, leading to excessive hemolysis.7 When excessive hemolysis occurs, the toxic contents of red blood cells are released into the bloodstream and cause many of the symptoms associated with PNH.



IMPORTANT SAFETY INFORMATION

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

Soliris® increases the risk of meningococcal infections

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).